Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome
Taysha Gene Therapies, Inc., a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels, Belgium from October 24 - 27, 2023.